ES2061591T3 - Administracion intranasal de polipeptidos en forma pulverizada. - Google Patents

Administracion intranasal de polipeptidos en forma pulverizada.

Info

Publication number
ES2061591T3
ES2061591T3 ES88117029T ES88117029T ES2061591T3 ES 2061591 T3 ES2061591 T3 ES 2061591T3 ES 88117029 T ES88117029 T ES 88117029T ES 88117029 T ES88117029 T ES 88117029T ES 2061591 T3 ES2061591 T3 ES 2061591T3
Authority
ES
Spain
Prior art keywords
polypeptides
intranasal administration
sprayed form
biologically active
sprayed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88117029T
Other languages
English (en)
Inventor
Brian H Vickery
Cherng-Chyi Fu
Eric J Benjamin
Lynda M Sanders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2061591T3 publication Critical patent/ES2061591T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPUESTOS FARMACEUTICOS DE POLIPEPTIDOS ACTIVOS BIOLOGICAMENTE EN FORMA PULVURULENTA APROPIADOS PARA ADMINISTRACION NASAL, COMPRENDEN UNA CANTIDAD TERAPEUTICA EFECTIVA DE POLIPEPTIDOS BIOLOGICAMENTE ACTIVOS Y UN POLISACARIDO SOLUBLE EN AGUA.
ES88117029T 1987-10-15 1988-10-13 Administracion intranasal de polipeptidos en forma pulverizada. Expired - Lifetime ES2061591T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10967887A 1987-10-15 1987-10-15

Publications (1)

Publication Number Publication Date
ES2061591T3 true ES2061591T3 (es) 1994-12-16

Family

ID=22328950

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88117029T Expired - Lifetime ES2061591T3 (es) 1987-10-15 1988-10-13 Administracion intranasal de polipeptidos en forma pulverizada.

Country Status (11)

Country Link
US (3) US6521597B1 (es)
EP (1) EP0312052B1 (es)
JP (1) JP2851627B2 (es)
KR (1) KR890006252A (es)
AT (1) ATE99543T1 (es)
AU (1) AU623609B2 (es)
CA (1) CA1336401C (es)
DE (1) DE3886880T2 (es)
ES (1) ES2061591T3 (es)
NZ (1) NZ226557A (es)
ZA (1) ZA887658B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
EP0565722A1 (en) * 1990-12-25 1993-10-20 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical preparation for pernasal administration
WO1993006862A1 (fr) * 1991-10-11 1993-04-15 Toray Industries, Inc. Composition a base d'anticorps
WO1993019771A1 (en) * 1992-03-27 1993-10-14 Kirin Brewery Company, Limited Pernasal preparation containing granulocyte colony-stimulating factor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
KR100389080B1 (ko) 1994-12-22 2003-10-17 아스트라제네카 악티에볼라그 부갑상선호르몬(pth)을포함하는흡입용치료제제
HUT77775A (hu) 1994-12-22 1998-08-28 Astra Aktiebolag Aeroszolformák
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
PT909175E (pt) * 1996-07-03 2003-10-31 Alza Corp Formulacoes nao aquosas de peptidos proticos
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
BR9912395A (pt) 1998-07-24 2001-10-16 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
US7893021B2 (en) * 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
WO2001056547A2 (en) 2000-02-04 2001-08-09 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20040152639A1 (en) * 2001-08-28 2004-08-05 Siler-Khodr Theresa M. Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
EP1458362A4 (en) * 2001-11-19 2006-01-18 Becton Dickinson Co PHARMACEUTICAL COMPOSITIONS IN PARTICLE FORM
CA2468250A1 (en) * 2001-11-26 2003-06-05 Daiichi Suntory Pharma Co., Ltd. Pharmaceutical composition for nasal absorption
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
KR20070007086A (ko) * 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
EP1785145A4 (en) 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
US8173627B2 (en) 2004-08-30 2012-05-08 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
EP1809330B1 (en) 2004-10-15 2011-04-27 Seo Hong Yoo Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin
KR100834735B1 (ko) * 2004-11-15 2008-06-09 김두만 부신피질 기능 부전증 치료용 부신피질 자극 호르몬의비강 분무 제형
CN101151533A (zh) * 2005-02-16 2008-03-26 伊利诺斯大学理事会 基于金属螯合脂质的促凝血剂
CA2600907C (en) * 2005-03-04 2016-06-28 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
EP2056800B1 (en) * 2005-08-26 2015-12-09 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
WO2008005577A2 (en) * 2006-07-07 2008-01-10 University Of South Florida Compositions of polyphenols and methods of use
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
WO2008147807A2 (en) 2007-05-23 2008-12-04 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
WO2009023125A1 (en) * 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
AU2008306192A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of leptin (22-56 ) as a therapeutic agent
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
WO2009061697A1 (en) * 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
CN102014636A (zh) 2008-02-27 2011-04-13 安姆科尔国际公司 治疗和动脉粥样硬化有关的心血管障碍的方法
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
CA2972975A1 (en) 2015-01-07 2016-07-14 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN110279656B (zh) * 2019-07-11 2021-11-09 温州医科大学 一种用于缓解鼻腔干燥的组合物及其制备方法和使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4320118A (en) * 1980-12-22 1982-03-16 Syntex (U.S.A.) Inc. Deca-, undeca-, dodeca- and tridecapeptides with thymic activity
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4659693A (en) * 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4690916A (en) * 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
JPS61144949A (ja) * 1984-12-18 1986-07-02 Nec Corp 着信側加入者端末の状態監視方式
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US4758584A (en) * 1987-02-05 1988-07-19 Ciba-Geigy Corporation Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation

Also Published As

Publication number Publication date
ATE99543T1 (de) 1994-01-15
US20030181387A1 (en) 2003-09-25
US20050089480A1 (en) 2005-04-28
KR890006252A (ko) 1989-06-12
ZA887658B (en) 1990-06-27
CA1336401C (en) 1995-07-25
US6521597B1 (en) 2003-02-18
JPH01132532A (ja) 1989-05-25
US6815424B2 (en) 2004-11-09
EP0312052A1 (en) 1989-04-19
DE3886880D1 (de) 1994-02-17
NZ226557A (en) 1990-07-26
JP2851627B2 (ja) 1999-01-27
AU623609B2 (en) 1992-05-21
DE3886880T2 (de) 1994-07-14
EP0312052B1 (en) 1994-01-05
AU2375188A (en) 1989-06-01

Similar Documents

Publication Publication Date Title
ES2061591T3 (es) Administracion intranasal de polipeptidos en forma pulverizada.
LV10196A (lv) Olbaltumviela biologiski aktivais hormons olbaltumvielas iegusanas panemiens farmaceitisks preparats
IL74804A0 (en) Human physiologically active polypeptide,its production and pharmaceutical compositions containing it
FI870809A (fi) Menetelmä farmaseuttisessa valmisteessa käytettävän, veteen liukenevan, biologisesti aktiivisen, konjugoidun proteiinin valmistamiseksi
EP0928189A4 (en) ADMINISTRATION OF A BIOLOGICALLY ACTIVE MATERIAL IN A LIPOSOME FORMULATION INTO THE MOUTH
WO1997014806A3 (en) Delivery of biologically active polypeptides
GR1003711B (el) Μεθοδος δια την παρασκευη φαρμακευτικων συνθεσεων δια συστηματικην διαδερμικην χορηγησιν.
IL90550A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
HK18796A (en) New amino acid derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
EP0474453A3 (en) Pharmaceutical composition comprising an active peptide or protein and a heat-labile enterotoxin b and its mucous use
EP0340333A3 (en) Novel physiologically active polypeptide and pharmaceutical composition
EP0305551A3 (en) Pharmaceutical compositions for topical application
EP0177342A3 (en) Oral formulation of therapeutic proteins
NZ237930A (en) Wafer for administration of medicaments through the sub-lingual mucosa
EP0129582A4 (en) BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS FOR ORAL ADMINISTRATION.
IL91856A0 (en) Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same
SE8601457D0 (sv) Compositions of liposomes and b?712-receptor active substances for inhalation
EP0030847A3 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
NO863027D0 (no) Peptidpreparater med kontinuerlig avgivelse.
DE3067790D1 (en) Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them
IL49423A0 (en) Pharmaceutical compositions comprising biologically active polypeptides
IT8921567A0 (it) Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono.
NZ227880A (en) Pyridyl substituted 1,3 dioxane alkenoic acid derivatives and pharmaceutical compositions
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions
EP0296227A4 (en) ADMINISTRATION OF AMINOACIDS BY NASAL ROUTE.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 312052

Country of ref document: ES